Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 148

1.

Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up.

Pothuri B, Brodsky AL, Sparano JA, Blank SV, Kim M, Hershman DL, Tiersten A, Kiesel BF, Beumer JH, Liebes L, Muggia F.

Cancer Chemother Pharmacol. 2020 Apr;85(4):741-751. doi: 10.1007/s00280-020-04030-2. Epub 2020 Feb 13.

PMID:
32055930
2.

Triple drugs co-delivered by a small gemcitabine-based carrier for pancreatic cancer immunochemotherapy.

Sun J, Wan Z, Chen Y, Xu J, Luo Z, Parise RA, Diao D, Ren P, Beumer JH, Lu B, Li S.

Acta Biomater. 2020 Apr 1;106:289-300. doi: 10.1016/j.actbio.2020.01.039. Epub 2020 Jan 28.

PMID:
32004652
3.

Editorial.

Beumer JH.

Cancer Chemother Pharmacol. 2020 Jan;85(1):1. doi: 10.1007/s00280-020-04032-0. No abstract available.

PMID:
31974653
4.

Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies.

Siddiqi T, Frankel P, Beumer JH, Kiesel BF, Christner S, Ruel C, Song JY, Chen R, Kelly KR, Ailawadhi S, Kaesberg P, Popplewell L, Puverel S, Piekarz R, Forman SJ, Newman EM.

Leuk Lymphoma. 2020 Feb;61(2):309-317. doi: 10.1080/10428194.2019.1672052. Epub 2019 Oct 16.

PMID:
31617432
5.

Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies.

Appleman LJ, Beumer JH, Jiang Y, Lin Y, Ding F, Puhalla S, Swartz L, Owonikoko TK, Donald Harvey R, Stoller R, Petro DP, Tawbi HA, Argiris A, Strychor S, Pouquet M, Kiesel B, Chen AP, Gandara D, Belani CP, Chu E, Ramalingam SS.

Cancer Chemother Pharmacol. 2019 Dec;84(6):1289-1301. doi: 10.1007/s00280-019-03960-w. Epub 2019 Sep 23.

PMID:
31549216
6.

Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial.

Luu T, Frankel P, Beumer JH, Lim D, Cristea M, Appleman LJ, Lenz HJ, Gandara DR, Kiesel BF, Piekarz RL, Newman EM.

Cancer Chemother Pharmacol. 2019 Dec;84(6):1201-1208. doi: 10.1007/s00280-019-03955-7. Epub 2019 Sep 14.

PMID:
31522242
7.

Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10.

Abraham J, Montero AJ, Jankowitz RC, Salkeni MA, Beumer JH, Kiesel BF, Piette F, Adamson LM, Nagy RJ, Lanman RB, Sperinde J, Huang W, Allegra CJ, Srinivasan A, Wang Y, Pogue-Geile KL, Lucas PC, Jacobs SA.

J Clin Oncol. 2019 Oct 10;37(29):2601-2609. doi: 10.1200/JCO.19.00858. Epub 2019 Aug 23.

8.

Combination Therapy with Disulfiram, Copper, and Doxorubicin for Osteosarcoma: In Vitro Support for a Novel Drug Repurposing Strategy.

Mandell JB, Lu F, Fisch M, Beumer JH, Guo J, Watters RJ, Weiss KR.

Sarcoma. 2019 Jul 11;2019:1320201. doi: 10.1155/2019/1320201. eCollection 2019.

9.

A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction.

Takebe N, Beumer JH, Kummar S, Kiesel BF, Dowlati A, O'Sullivan Coyne G, Piekarz R, Rubinstein L, Fogli LK, Vaishampayan U, Goel S, O'Bryant CL, El-Rayes BF, Chung V, Lenz HJ, Kim R, Belani CP, Tuscano JM, Schelman W, Moore N, Doroshow JH, Chen AP.

Br J Clin Pharmacol. 2019 Nov;85(11):2499-2511. doi: 10.1111/bcp.14054. Epub 2019 Sep 4.

10.

Quantitation of paclitaxel, and its 6-alpha-OH and 3-para-OH metabolites in human plasma by LC-MS/MS.

Christner SM, Parise RA, Ivy PS, Tawbi H, Chu E, Beumer JH.

J Pharm Biomed Anal. 2019 Aug 5;172:26-32. doi: 10.1016/j.jpba.2019.04.027. Epub 2019 Apr 15.

PMID:
31022613
11.

Estimation of Kidney Function in Oncology: Implications for Anticancer Drug Selection and Dosing.

Casal MA, Nolin TD, Beumer JH.

Clin J Am Soc Nephrol. 2019 Apr 5;14(4):587-595. doi: 10.2215/CJN.11721018. Epub 2019 Mar 19.

12.

Oligoadenylate-Synthetase-Family Protein OASL Inhibits Activity of the DNA Sensor cGAS during DNA Virus Infection to Limit Interferon Production.

Ghosh A, Shao L, Sampath P, Zhao B, Patel NV, Zhu J, Behl B, Parise RA, Beumer JH, O'Sullivan RJ, DeLuca NA, Thorne SH, Rathinam VAK, Li P, Sarkar SN.

Immunity. 2019 Jan 15;50(1):51-63.e5. doi: 10.1016/j.immuni.2018.12.013. Epub 2019 Jan 8.

13.

A window-of-opportunity clinical trial of dasatinib in women with newly diagnosed endometrial cancer.

Duska LR, Petroni GR, Lothamer H, Faust W Jr, Beumer JH, Christner SM, Mills AM, Fracasso PM, Parsons SJ.

Cancer Chemother Pharmacol. 2019 Mar;83(3):473-482. doi: 10.1007/s00280-018-3749-7. Epub 2018 Dec 8.

14.

Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias.

Singh R, Mehrotra S, Gopalakrishnan M, Gojo I, Karp JE, Greer JM, Chen A, Piekarz R, Kiesel BF, Gobburu J, Rudek MA, Beumer JH; ETCTN-6745 study team.

Cancer Chemother Pharmacol. 2019 Feb;83(2):319-328. doi: 10.1007/s00280-018-3731-4. Epub 2018 Nov 20.

15.

NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma.

Burton JH, Mazcko C, LeBlanc A, Covey JM, Ji J, Kinders RJ, Parchment RE, Khanna C, Paoloni M, Lana S, Weishaar K, London C, Kisseberth W, Krick E, Vail D, Childress M, Bryan JN, Barber L, Ehrhart EJ, Kent M, Fan T, Kow K, Northup N, Wilson-Robles H, Tomaszewski J, Holleran JL, Muzzio M, Eiseman J, Beumer JH, Doroshow JH, Pommier Y.

Clin Cancer Res. 2018 Dec 1;24(23):5830-5840. doi: 10.1158/1078-0432.CCR-18-1498. Epub 2018 Jul 30.

16.

ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation.

Vendetti FP, Karukonda P, Clump DA, Teo T, Lalonde R, Nugent K, Ballew M, Kiesel BF, Beumer JH, Sarkar SN, Conrads TP, O'Connor MJ, Ferris RL, Tran PT, Delgoffe GM, Bakkenist CJ.

J Clin Invest. 2018 Aug 31;128(9):3926-3940. doi: 10.1172/JCI96519. Epub 2018 Aug 13.

17.

Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy.

Beumer JH, Chu E, Allegra C, Tanigawara Y, Milano G, Diasio R, Kim TW, Mathijssen RH, Zhang L, Arnold D, Muneoka K, Boku N, Joerger M.

Clin Pharmacol Ther. 2019 Mar;105(3):598-613. doi: 10.1002/cpt.1124. Epub 2018 Sep 11. Review.

18.

Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi.

Tahata S, Singh SV, Lin Y, Hahm ER, Beumer JH, Christner SM, Rao UN, Sander C, Tarhini AA, Tawbi H, Ferris LK, Wilson M, Rose A, Dietz CM, Hughes E, Fahey JW, Leachman SA, Cassidy PB, Butterfield LH, Zarour HM, Kirkwood JM.

Cancer Prev Res (Phila). 2018 Jul;11(7):429-438. doi: 10.1158/1940-6207.CAPR-17-0268. Epub 2018 Apr 24.

19.

A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia.

Redner RL, Beumer JH, Kropf P, Agha M, Boyiadzis M, Dorritie K, Farah R, Hou JZ, Im A, Lim SH, Raptis A, Sehgal A, Christner SM, Normolle D, Johnson DE.

Leuk Lymphoma. 2018 Nov;59(11):2595-2601. doi: 10.1080/10428194.2018.1443330. Epub 2018 Apr 4.

20.

Targeting p53-dependent stem cell loss for intestinal chemoprotection.

Leibowitz BJ, Yang L, Wei L, Buchanan ME, Rachid M, Parise RA, Beumer JH, Eiseman JL, Schoen RE, Zhang L, Yu J.

Sci Transl Med. 2018 Feb 7;10(427). pii: eaam7610. doi: 10.1126/scitranslmed.aam7610.

21.

Development and Validation of a Bioanalytical Method to Quantitate Enzalutamide and its Active Metabolite N-Desmethylenzalutamide in Human Plasma: Application to Clinical Management of Patients With Metastatic Castration-Resistant Prostate Cancer.

Benoist GE, van der Meulen E, van Oort IM, Beumer JH, Somford DM, Schalken JA, Burger DM, van Erp NP.

Ther Drug Monit. 2018 Apr;40(2):222-229. doi: 10.1097/FTD.0000000000000484.

22.

Liquid chromatography-tandem mass spectrometric assay for the quantitation of the novel radiation protective agent and radiation mitigator JP4-039 in murine plasma.

Christner S, Guo J, Parise RA, Ringeval M, Hoye AT, Wipf P, Epperly MW, Greenberger JS, Beumer JH, Eiseman JL.

J Pharm Biomed Anal. 2018 Feb 20;150:169-175. doi: 10.1016/j.jpba.2017.12.023. Epub 2017 Dec 12.

23.

Improving Carboplatin Dosing Based on EstimatedĀ GFR.

Beumer JH, Inker LA, Levey AS.

Am J Kidney Dis. 2018 Feb;71(2):163-165. doi: 10.1053/j.ajkd.2017.10.005. Epub 2017 Dec 6. No abstract available.

24.

Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease.

Chen GL, Carpenter PA, Broady R, Gregory TK, Johnston LJ, Storer BE, Beumer JH, Qiu J, Cerda K, Le R, Otani JM, Liu H, Ross MA, Arai S, Flowers MED, McCarthy PL, Miklos DB.

Biol Blood Marrow Transplant. 2018 Feb;24(2):373-380. doi: 10.1016/j.bbmt.2017.10.021. Epub 2017 Oct 16.

25.

Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer.

Luu T, Kim KP, Blanchard S, Anyang B, Hurria A, Yang L, Beumer JH, Somlo G, Yen Y.

Breast Cancer Res Treat. 2018 Jan;167(2):469-478. doi: 10.1007/s10549-017-4516-x. Epub 2017 Sep 27.

PMID:
28956187
26.

Estimation of body surface area in the musk shrew ( Suncus murinus): a small animal for testing chemotherapy-induced emesis.

Eiseman JL, Sciullo M, Wang H, Beumer JH, Horn CC.

Lab Anim. 2017 Oct;51(5):534-537. doi: 10.1177/0023677217695851. Epub 2017 Feb 26.

27.

LC-MS/MS assay for the quantitation of the ATR kinase inhibitor VX-970 in human plasma.

Kiesel BF, Scemama J, Parise RA, Villaruz L, Iffland A, Doyle A, Ivy P, Chu E, Bakkenist CJ, Beumer JH.

J Pharm Biomed Anal. 2017 Nov 30;146:244-250. doi: 10.1016/j.jpba.2017.08.037. Epub 2017 Aug 31.

28.

LC-MS/MS assay for the quantitation of the ribonucleotide reductase inhibitor triapine in human plasma.

Matsumoto J, Kiesel BF, Parise RA, Guo J, Taylor S, Huang M, Eiseman JL, Ivy SP, Kunos C, Chu E, Beumer JH.

J Pharm Biomed Anal. 2017 Nov 30;146:154-160. doi: 10.1016/j.jpba.2017.08.036. Epub 2017 Aug 31.

29.

Phase I study of veliparib in combination with gemcitabine.

Stoller R, Schmitz JC, Ding F, Puhalla S, Belani CP, Appleman L, Lin Y, Jiang Y, Almokadem S, Petro D, Holleran J, Kiesel BF, Ken Czambel R, Carneiro BA, Kontopodis E, Hershberger PA, Rachid M, Chen A, Chu E, Beumer JH.

Cancer Chemother Pharmacol. 2017 Sep;80(3):631-643. doi: 10.1007/s00280-017-3409-3. Epub 2017 Aug 2.

30.

Rapid Homogeneous Immunoassay to Quantify Gemcitabine in Plasma for Therapeutic Drug Monitoring.

Kozo D, Ross MW, Jarrah J, Barrett M, Harney RL, Courtney JB, Baburina I, Holleran JL, Beumer JH, Peters GJ, Honeywell RJ, Salamone SJ.

Ther Drug Monit. 2017 Jun;39(3):235-242. doi: 10.1097/FTD.0000000000000402.

31.

Parent-Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT-888), a PARP Inhibitor, in Patients With BRCA 1/2-Mutated Cancer or PARP-Sensitive Tumor Types.

Niu J, Scheuerell C, Mehrotra S, Karan S, Puhalla S, Kiesel BF, Ji J, Chu E, Gopalakrishnan M, Ivaturi V, Gobburu J, Beumer JH.

J Clin Pharmacol. 2017 Aug;57(8):977-987. doi: 10.1002/jcph.892. Epub 2017 Apr 7.

32.

Analytical challenges in quantifying abiraterone with LC-MS/MS in human plasma.

Benoist GE, van der Meulen E, Lubberman FJE, Gerritsen WR, Smilde TJ, Schalken JA, Beumer JH, Burger DM, van Erp NP.

Biomed Chromatogr. 2017 Nov;31(11). doi: 10.1002/bmc.3986. Epub 2017 May 16.

33.

Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083.

Somlo G, Frankel PH, Arun BK, Ma CX, Garcia AA, Cigler T, Cream LV, Harvey HA, Sparano JA, Nanda R, Chew HK, Moynihan TJ, Vahdat LT, Goetz MP, Beumer JH, Hurria A, Mortimer J, Piekarz R, Sand S, Herzog J, Van Tongeren LR, Ferry-Galow KV, Chen AP, Ruel C, Newman EM, Gandara DR, Weitzel JN.

Clin Cancer Res. 2017 Aug 1;23(15):4066-4076. doi: 10.1158/1078-0432.CCR-16-2714. Epub 2017 Mar 29.

34.

A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.

Jandial DA, Brady WE, Howell SB, Lankes HA, Schilder RJ, Beumer JH, Christner SM, Strychor S, Powell MA, Hagemann AR, Moore KN, Walker JL, DiSilvestro PA, Duska LR, Fracasso PM, Dizon DS.

Gynecol Oncol. 2017 May;145(2):236-242. doi: 10.1016/j.ygyno.2017.03.013. Epub 2017 Mar 22.

35.

The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.

Soumerai JD, Zelenetz AD, Moskowitz CH, Palomba ML, Hamlin PA Jr, Noy A, Straus DJ, Moskowitz AJ, Younes A, Matasar MJ, Horwitz SM, Portlock CS, Konner JA, Gounder MM, Hyman DM, Voss MH, Fury MG, Gajria D, Carvajal RD, Ho AL, Beumer JH, Kiesel B, Zhang Z, Chen A, Little RF, Jarjies C, Dang TO, France F, Mishra N, Gerecitano JF.

Clin Cancer Res. 2017 Aug 1;23(15):4119-4126. doi: 10.1158/1078-0432.CCR-16-3068. Epub 2017 Mar 17.

36.

A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study.

Rader JS, Sill MW, Beumer JH, Lankes HA, Benbrook DM, Garcia F, Trimble C, Tate Thigpen J, Lieberman R, Zuna RE, Leath CA 3rd, Spirtos NM, Byron J, Thaker PH, Lele S, Alberts D.

Gynecol Oncol. 2017 May;145(2):291-297. doi: 10.1016/j.ygyno.2017.02.040. Epub 2017 Mar 10.

37.

RAD-ADAPT: Software for modelling clonogenic assay data in radiation biology.

Zhang Y, Hu K, Beumer JH, Bakkenist CJ, D'Argenio DZ.

DNA Repair (Amst). 2017 Apr;52:24-30. doi: 10.1016/j.dnarep.2017.02.004. Epub 2017 Feb 20.

38.

Simultaneous quantitation of abiraterone, enzalutamide, N-desmethyl enzalutamide, and bicalutamide in human plasma by LC-MS/MS.

Kim KP, Parise RA, Holleran JL, Lewis LD, Appleman L, van Erp N, Morris MJ, Beumer JH.

J Pharm Biomed Anal. 2017 May 10;138:197-205. doi: 10.1016/j.jpba.2017.02.018. Epub 2017 Feb 13.

39.

LC-MS/MS assay for the simultaneous quantitation of the ATM inhibitor AZ31 and the ATR inhibitor AZD6738 in mouse plasma.

Kiesel BF, Shogan JC, Rachid M, Parise RA, Vendetti FP, Bakkenist CJ, Beumer JH.

J Pharm Biomed Anal. 2017 May 10;138:158-165. doi: 10.1016/j.jpba.2017.01.055. Epub 2017 Feb 4.

40.

Pharmacologic ATM but not ATR kinase inhibition abrogates p21-dependent G1 arrest and promotes gastrointestinal syndrome after total body irradiation.

Vendetti FP, Leibowitz BJ, Barnes J, Schamus S, Kiesel BF, Abberbock S, Conrads T, Clump DA, Cadogan E, O'Connor MJ, Yu J, Beumer JH, Bakkenist CJ.

Sci Rep. 2017 Feb 1;7:41892. doi: 10.1038/srep41892.

41.

Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study.

von Gruenigen VE, Huang HQ, Beumer JH, Lankes HA, Tew W, Herzog T, Hurria A, Mannel RS, Rizack T, Landrum LM, Rose PG, Salani R, Bradley WH, Rutherford TJ, Higgins RV, Secord AA, Fleming G.

Gynecol Oncol. 2017 Mar;144(3):459-467. doi: 10.1016/j.ygyno.2016.11.033. Epub 2017 Jan 13.

42.

Disease Subtype-Independent Biomarkers of Breast Cancer Chemoprevention by the Ayurvedic Medicine Phytochemical Withaferin A.

Samanta SK, Sehrawat A, Kim SH, Hahm ER, Shuai Y, Roy R, Pore SK, Singh KB, Christner SM, Beumer JH, Davidson NE, Singh SV.

J Natl Cancer Inst. 2016 Dec 31;109(6). doi: 10.1093/jnci/djw293. Print 2017 Jun.

43.

LC-MS/MS assay for the quantitation of the tyrosine kinase inhibitor neratinib in human plasma.

Kiesel BF, Parise RA, Wong A, Keyvanjah K, Jacobs S, Beumer JH.

J Pharm Biomed Anal. 2017 Feb 5;134:130-136. doi: 10.1016/j.jpba.2016.11.035. Epub 2016 Nov 22.

44.

Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies.

Kunos CA, Chu E, Beumer JH, Sznol M, Ivy SP.

Cancer Chemother Pharmacol. 2017 Jan;79(1):201-207. doi: 10.1007/s00280-016-3200-x. Epub 2016 Nov 22.

45.

Erratum to: Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors.

Edelman MJ, Lapidus R, Feliciano J, Styblo M, Beumer JH, Liu T, Gobburu J.

Cancer Chemother Pharmacol. 2016 Nov;78(5):969. No abstract available.

PMID:
27677624
46.

Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors.

Edelman MJ, Lapidus R, Feliciano J, Styblo M, Beumer JH, Liu T, Gobbru J.

Cancer Chemother Pharmacol. 2016 Nov;78(5):959-967. Epub 2016 Sep 12. Erratum in: Cancer Chemother Pharmacol. 2016 Nov;78(5):969.

PMID:
27620207
47.

Toxicity, pharmacokinetics and metabolism of a novel inhibitor of IL-6-induced STAT3 activation.

Kiesel BF, Parise RA, Guo J, Huryn DM, Johnston PA, Colombo R, Sen M, Grandis JR, Beumer JH, Eiseman JL.

Cancer Chemother Pharmacol. 2016 Dec;78(6):1225-1235. doi: 10.1007/s00280-016-3181-9. Epub 2016 Oct 24.

48.

A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia.

Gojo I, Beumer JH, Pratz KW, McDevitt MA, Baer MR, Blackford AL, Smith BD, Gore SD, Carraway HE, Showel MM, Levis MJ, Dezern AE, Gladstone DE, Ji JJ, Wang L, Kinders RJ, Pouquet M, Ali-Walbi I, Rudek MA, Poh W, Herman JG, Karnitz LM, Kaufmann SH, Chen A, Karp JE.

Clin Cancer Res. 2017 Feb 1;23(3):697-706. doi: 10.1158/1078-0432.CCR-16-0984. Epub 2016 Aug 8.

49.

Tyrosine Kinase and Mammalian Target of Rapamycin Inhibitors in the Treatment of Advanced Renal Cell Carcinoma: Practical Clinical Implications of Pharmacologic Features.

Parikh RA, Appleman LJ, Beumer JH, Matczak E, Chu E.

Clin Genitourin Cancer. 2017 Feb;15(1):7-22. doi: 10.1016/j.clgc.2016.05.011. Epub 2016 May 31. Review.

PMID:
27473523
50.

LC-MS/MS assay for the quantitation of FdCyd and its metabolites FdUrd and FU in human plasma.

Holleran JL, Eiseman JL, Parise RA, Kummar S, Beumer JH.

J Pharm Biomed Anal. 2016 Sep 10;129:359-366. doi: 10.1016/j.jpba.2016.07.027. Epub 2016 Jul 18.

Supplemental Content

Loading ...
Support Center